Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAIA: Extension Trial of Bimatoprost SR in Open Angle Glaucoma or Ocular Hypertension
NCT03891446Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 26
01
Overview
Phase 3, open-label trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (4 arms), sponsored by AbbVie Inc. Primary endpoints: Duration of effect of Bimatoprost SR at 24 months and Number of patients experiencing a treatment emergent adverse event at 24 months. Started Mar 2019; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03891446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891446.